Chromadex Corp
NASDAQ:CDXC
Chromadex Corp
NASDAQ:CDXC
Price:
3.46 USD
0.58%
Updated:
Apr 29, 2024
P/E
Price to Earnings
Price to Earnings
-52.5
Current
-15.1
Median
30.3
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-52.5
Market Cap
/
259.4m
Net Income
-4.9m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Chromadex Corp
NASDAQ:CDXC
|
259.4m USD | -52.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
223.9B USD | 37.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
184B USD | 22.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.9B USD | 31.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.6B CHF | 57.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
40.8B USD | 33 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.2T KRW | 64.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 34.2 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.2B USD | 44.2 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
25.3B USD | 41.2 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.3B EUR | 76.7 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-253.4
2-Years Forward
P/E
63.3
3-Years Forward
P/E
30.7
You don't have any saved screeners yet
